Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease

被引:32
|
作者
Kushleika, J
Checkoway, H
Woods, JS
Moon, JD
SmithWellar, T
Franklin, GM
Swanson, PD
机构
[1] UNIV WASHINGTON,DEPT ENVIRONM HLTH,SEATTLE,WA 98195
[2] UNIV WASHINGTON,DEPT NEUROL,SEATTLE,WA 98195
[3] CHONNAM NATL UNIV,SCH MED,DEPT PREVENT MED,KWANGJU,SOUTH KOREA
关键词
D O I
10.1002/ana.410390315
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Superoxide dismutases (SODs) are metalloenzymes that detoxify superoxide radicals, and occur in cytosolic (Cu,Zn-SOD) and mitochondrial (Mn-SOD) forms in multiple tissues, including brain. A neuroprotective effect against oxide stressor exposures may be provided by SOD, although excessive enzyme activity can produce cell injury by formation of hydroxyl radical from hydrogen peroxide. We measured Cu,Zn-SOD and Mn-SOD activities in peripheral lymphocytes of 43 newly diagnosed idiopathic Parkinson's disease (PD) cases and 62 age- and sex-matched controls free of neurodegenerative disorders. Significant excesses of both SOD forms were found among PD cases compared with controls; however, the excesses were found exclusively among FD patients treated with the monoamine oxidase inhibitor selegiline (L-deprenyl). Enzyme-linked immunosorbent assays (ELISAs) confirmed that the activity excesses were due to increased protein rather than more highly reactive enzymes in lymphocytes of PD cases. Our findings clearly indicate the importance of selegiline on measured Cu,Zn-SOD and Mn-SOD activity in peripheral lymphocytes. Characterizing a possible therapeutic value of SOD will require longitudinal assessments of SOD in relation to PD progerssion.
引用
收藏
页码:378 / 381
页数:4
相关论文
共 50 条
  • [21] Orally disintegrating selegiline for the treatment of Parkinson's disease
    Loehle, Matthias
    Storch, Alexander
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (16) : 2881 - 2891
  • [22] Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
    Heinonen, EH
    Myllyla, V
    DRUG SAFETY, 1998, 19 (01) : 11 - 22
  • [23] Selegiline and blood pressure in patients with Parkinson's disease
    Pursiainen, V.
    Korpelainen, T. J.
    Haapaniemi, H. T.
    Sotaniemi, A. K.
    Myllyla, V. V.
    ACTA NEUROLOGICA SCANDINAVICA, 2007, 115 (02): : 104 - 108
  • [24] Role of selegiline in combination therapy of Parkinson's disease
    Myllyla, VV
    Sotaniemi, K
    MakiIkola, O
    Rinne, UK
    Heinonen, EH
    NEUROLOGY, 1996, 47 (06) : S200 - S209
  • [25] A novel formulation of selegiline for the treatment of Parkinson's disease
    Tetrud, JW
    Koller, WC
    NEUROLOGY, 2004, 63 (07) : S2 - S6
  • [26] Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data
    Ihara, Y
    Chuda, M
    Kuroda, S
    Hayabara, T
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 170 (02) : 90 - 95
  • [27] Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease
    Yoritaka, Asako
    Mori, Hideo
    Hattori, Nobutaka
    EUROPEAN NEUROLOGY, 2016, 76 (1-2) : 35 - 39
  • [28] Selegiline reduces daytime sleepiness in patients with Parkinson's disease
    Gallazzi, Marco
    Mauri, Marco
    Bianchi, Maria Laura
    Riboldazzi, Giulio
    Princiotta Cariddi, Lucia
    Carimati, Federico
    Rebecchi, Valentina
    Versino, Maurizio
    BRAIN AND BEHAVIOR, 2021, 11 (05):
  • [29] Selegiline in Parkinson's disease - No neuroprotective effect: Increased mortality
    Calne, DB
    BMJ-BRITISH MEDICAL JOURNAL, 1995, 311 (7020): : 1583 - 1584
  • [30] Current status of selegiline as a neuroprotective agent in Parkinson's disease
    Olanow, CW
    Mytilineou, C
    Tatton, W
    MOVEMENT DISORDERS, 1998, 13 : 55 - 58